Sep 21, 2022
Greg Frost is the Chairman and CEO of EXUMA Biotech, which is working on a cancer cellular therapy that can be administered in a patient without lymphodepletion from chemotherapy. Traditionally, it was thought that some cells needed to be eliminated before new cells could be introduced. EXUMA is working on a rapid point of care, rPOC, technology that will allow this approach to be expanded to various cancers and readily available to patients.
Greg explains, "What we came to realize was that if we were to take our gene-loaded lymphocytes, and rather than putting them directly in the bloodstream, if we allowed them to start through what we call a synthetic lymph node or a local injection site, that those cells could get the programming and expansion where they were rather than just going straight in the bloodstream and every cell was diluted out into different locations in the body."
"If they could start in one location together as a team, you had a much better chance of, when they would get into the lymphatics and build up through there, of having a stronger team to go in and fight the cancer. And importantly, also it makes it very effective for them to be able to amplify the gene programs that we have to get up into circulation without the need for lymphodepleting chemotherapy first."
@EXUMABiotech #CellularTherapy #SolidTumors #BloodCancers #Chemotherapy #Lymphodepletion #Cancer